Moderna and Merck's Cancer Vaccine Combo Shows Significant Benefit in Melanoma Trial

Moderna and Merck have announced promising results from their joint study of an mRNA-based therapy for cancer patients. The trial, which involved over 1,100 people with stage 2 to stage 4 melanoma, found that those who received Moderna's intismeran combined with Merck's Keytruda lived longer without recurrence and had fewer instances of the cancer spreading compared to those receiving Keytruda alone.

The study demonstrated a significant benefit for patients when combining the two therapies. 'What we're trying to do here is tell the immune system that it missed the signature of the tumor cell if you have cancer,' said Moderna CEO Stephane Bancel. Intismeran works by teaching the immune system about specific mutations in the cancer cells, allowing it to recognize and attack them.

The mRNA platform's ability to generate genetic sequences quickly is a key advantage for scaling up more personalized cancer treatment approaches. Keytruda, on the other hand, works by unveiling the cancer cells that often hide from the immune system.